At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 48 enrolled
Drug / intervention
Medroxyprogesterone 17-Acetate +1 moredrug
Likely dose
Medroxyprogesterone 17-Acetate 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial of Use of DMPA Injection and High Dose MPA Tablets in Outpatient
Women's Health Care Clinic, Torrance, California·interventional·Posted Jun 22, 2010·Updated Mar 13, 2014
In Brief
A Phase 4 clinical trial evaluating Medroxyprogesterone 17-Acetate and medroxyprogesterone acetate for Dysfunctional Uterine Bleeding. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysfunctional Uterine Bleeding
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJun 2010
Primary CompletionOct 2010
Study CompletionJul 2012
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2010
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.0 years ago
Interventions
Medroxyprogesterone 17-Acetatedrug
Medroxyprogesterone 20mg orally 3 times a day for 3 days
medroxyprogesterone acetatedrug
Depo Provera 150mg Intramuscular injection